COAG PE Ratio & Valuation, Is COAG Overvalued

Performance Decomposition

AI Analysis

Market capitalization of COAG increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of COAG in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is COAG currently overvalued or undervalued?

Hemab Therapeutics Holdings Inc (COAG) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Hemab Therapeutics Holdings Inc (COAG) is between -- to -- according to relative valuation method.

What is Hemab Therapeutics Holdings Inc (COAG) fair value?

COAG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Hemab Therapeutics Holdings Inc (COAG) is between -- to -- according to relative valuation method.

How does COAG's valuation metrics compare to the industry average?

The average P/S ratio for COAG's competitors is 0.00, providing a benchmark for relative valuation. Hemab Therapeutics Holdings Inc Corp (COAG) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for Hemab Therapeutics Holdings Inc (COAG) as of May 01 2026?

As of May 01 2026, Hemab Therapeutics Holdings Inc (COAG) has a P/B ratio of NaN. This indicates that the market values COAG at NaN times its book value.

What is the current FCF Yield for Hemab Therapeutics Holdings Inc (COAG) as of May 01 2026?

As of May 01 2026, Hemab Therapeutics Holdings Inc (COAG) has a FCF Yield of NaN%. This means that for every dollar of Hemab Therapeutics Holdings Inc's market capitalization, the company generates NaN cents in free cash flow.

What is the current Forward P/E ratio for Hemab Therapeutics Holdings Inc (COAG) as of May 01 2026?

As of May 01 2026, Hemab Therapeutics Holdings Inc (COAG) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Hemab Therapeutics Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Hemab Therapeutics Holdings Inc (COAG) as of May 01 2026?

As of May 01 2026, Hemab Therapeutics Holdings Inc (COAG) has a Forward P/S ratio of NaN. This means the market is valuing COAG at $NaN for every dollar of expected revenue over the next 12 months.

COAG Valuation